Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bierbeek – page 63

1 924 clinical trials in Bierbeek, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bierbeek at a glance
1 924
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 924 trials in Bierbeek

Open in trial search

Neoplasm malignant

Not yet recruiting

Phase 1/2 study of AVZO-023 drug combination in patients with advanced cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Avenzo Therapeutics Inc.

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Colorectal cancer

Not yet recruiting

A phase 1/2 study evaluating safety, pharmacokinetics and efficacy of SOT109 in patients with advanced unresectable or metastatic colorectal cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:SOTIO Biotech a.s.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Immune Response of GBS-NN/NN2 and Tdap Vaccines in Preventing Group B Strep Infection in Healthy Women Aged 18-49

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Psoriasis+1

Not yet recruiting

Diagnostic PET/CT Study with [AL[18F]F]FAPI-74 in Psoriasis Patients with Arthralgia for Early Detection of Psoriatic Arthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bierbeek

What the registry says about research in the country

01 Mental Health Research

Ongoing clinical investigations focusing on schizophrenia and cognitive impairment, evaluating long-term safety profiles of innovative therapeutic approaches.

  • Cognitive Function Assessment
  • Treatment Safety Evaluation
  • Extended Care Studies

This research builds upon previous clinical trials, specifically examining the continued effectiveness and safety of iclepertin in patients who have completed earlier treatment phases.

02 Psychiatric Therapeutics

Advanced research in psychiatric treatment focusing on developing safer, more effective therapies for individuals with chronic mental health conditions.

  • Long-term Safety Monitoring
  • Patient Follow-up Studies
  • Treatment Efficacy Assessment

The studies aim to enhance understanding of long-term therapeutic outcomes in patients with cognitive impairment related to schizophrenia.

03 Cognitive Health Studies

Comprehensive research examining the intersection of cognitive function and mental health conditions, with a focus on therapeutic interventions.

  • Cognitive Performance Evaluation
  • Extended Treatment Benefits
  • Safety Profile Analysis

These trials represent continued efforts to improve treatment options for individuals affected by cognitive challenges associated with psychiatric conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.